These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 17515120

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Intestinal bleeding during the treatment of chronic myeloid leukemia with imatinib mesylate].
    Yokote T, Akioka T, Nakayama S, Oka S, Hara S, Yamano T, Tsuji M, Hanafusa T.
    Rinsho Ketsueki; 2005 Sep; 46(9):1060-4. PubMed ID: 16440765
    [Abstract] [Full Text] [Related]

  • 27. Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
    Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J.
    J Clin Oncol; 2006 Mar 01; 24(7):1204-8. PubMed ID: 16446320
    [Abstract] [Full Text] [Related]

  • 28. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
    Breccia M, Cannella L, Stefanizzi C, Santopietro M, De Cuia R, Diverio D, Alimena G.
    Leuk Res; 2009 May 01; 33(5):645-8. PubMed ID: 19062090
    [Abstract] [Full Text] [Related]

  • 29. Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures.
    Chávez-González A, Ayala-Sánchez M, Sánchez-Valle E, Ruiz-Sánchez E, Arana-Trejo RM, Vela-Ojeda J, Mayani H.
    Leuk Res; 2006 Mar 01; 30(3):286-95. PubMed ID: 16111748
    [Abstract] [Full Text] [Related]

  • 30. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T, Tauchi T, Ohyashiki K.
    Rinsho Ketsueki; 2009 Jan 01; 50(1):52-4. PubMed ID: 19225231
    [Abstract] [Full Text] [Related]

  • 31. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
    de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, Szydlo R, Olavarria E, Kaeda J, Goldman JM, Marin D.
    J Clin Oncol; 2008 Jul 10; 26(20):3358-63. PubMed ID: 18519952
    [Abstract] [Full Text] [Related]

  • 32. Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.
    Singh T, Casson C.
    Am J Ther; 2007 Jul 10; 14(5):484-7. PubMed ID: 17890939
    [Abstract] [Full Text] [Related]

  • 33. Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study.
    Piccaluga PP, Malagola M, Rondoni M, Arpinati M, Paolini S, Candoni A, Fanin R, Messa E, Pirrotta MT, Lauria F, Visani G, Alberti D, Rancati F, Vinaccia V, Russo D, Saglio G, Baccarani M, Martinelli G.
    Haematologica; 2007 Dec 10; 92(12):1721-2. PubMed ID: 18056005
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
    Ernst T, Erben P, Müller MC, Paschka P, Schenk T, Hoffmann J, Kreil S, La Rosée P, Hehlmann R, Hochhaus A.
    Haematologica; 2008 Feb 10; 93(2):186-92. PubMed ID: 18223278
    [Abstract] [Full Text] [Related]

  • 37. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH, Popradi G, Sriharsha L, Kamel-Reid S, Chang H, Messner HA, Lipton JH.
    Cancer; 2008 Aug 15; 113(4):772-81. PubMed ID: 18543309
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenic response after interferon-alpha results in a very high complete molecular response rate.
    Alimena G, Breccia M, Luciano L, Quarantelli F, Diverio D, Izzo B, De Angelis B, Mancini M, Latagliata R, Carmosino I, Nanni M, Picardi M, Rotoli B, Mandelli F, Pane F.
    Leuk Res; 2008 Feb 15; 32(2):255-61. PubMed ID: 17692911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.